Mineralys Therapeutics (MLYS) Earnings Date, Estimates & Call Transcripts $9.24 -0.26 (-2.74%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Mineralys Therapeutics Latest Earnings SummaryUpcoming Q4 Earnings DateMar. 20After Market ClosesEstimatedActual EPS (Nov. 11) -$1.13 Missed By -$0.30 Consensus EPS (Nov. 11) -$0.83 Mineralys Therapeutics issued Q3 2024 earnings on November 11, 2024, reporting an EPS of -$1.13, which missed the consensus estimate of -$0.83 by $0.30. With a trailing EPS of -$3.27, Mineralys Therapeutics' earnings are expected to decrease next year, from ($3.63) to ($4.07) per share. Conference CallConference Call TranscriptMLYS Upcoming EarningsMineralys Therapeutics' next earnings date is estimated for Thursday, March 20, 2025, based off prior year's reporting schedules. Get Mineralys Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mineralys Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataMLYS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.MLYS Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Mineralys Therapeutics Analyst EPS EstimatesCurrent Year EPS Consensus Estimate:($3.63) EPSNext Year EPS Consensus Estimate: ($4.07) EPS Mineralys Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 3/20/2025(Estimated)-------11/11/2024Q3 2024-$0.83-$1.13 -$0.30-$1.13--8/13/2024Q2 2024-$0.73-$0.83 -$0.10-$0.83--5/9/2024Q1 2024-$0.68-$0.70 -$0.02-$0.70--3/21/2024Q4 2023-$0.85-$0.61+$0.24-$0.61--11/7/2023Q3 2023-$0.72-$0.57+$0.15-$0.57--8/7/2023Q2 2023-$0.83-$0.31+$0.52-$0.31--5/15/2023Q1 2023-$0.71-$0.51+$0.20-$0.51--3/15/2023Q4 2022--$1.74 -$1.74-$1.74-- Mineralys Therapeutics Earnings - Frequently Asked Questions When is Mineralys Therapeutics's earnings date? Mineralys Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 20th, 2025 based off last year's report dates. Learn more on MLYS's earnings history. Did Mineralys Therapeutics beat their earnings estimates last quarter? In the previous quarter, Mineralys Therapeutics (NASDAQ:MLYS) missed the analysts' consensus estimate of ($0.83) by $0.30 with a reported earnings per share (EPS) of ($1.13). Learn more on analysts' earnings estimate vs. MLYS's actual earnings. How can I listen to Mineralys Therapeutics's earnings conference call? The conference call for Mineralys Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Mineralys Therapeutics's conference call transcript? The conference call transcript for Mineralys Therapeutics's latest earnings report can be read online. Read Transcript How much profit does Mineralys Therapeutics generate each year? Mineralys Therapeutics (NASDAQ:MLYS) has a recorded net income of -$71.90 million. MLYS has generated -$3.27 earnings per share over the last four quarters. What is Mineralys Therapeutics's EPS forecast for next year? Mineralys Therapeutics's earnings are expected to decrease from ($3.63) per share to ($4.07) per share in the next year. More Earnings Resources from MarketBeat Related Companies APGE Earnings Date AMPH Earnings Date TARS Earnings Date IOVA Earnings Date IRON Earnings Date IBRX Earnings Date WVE Earnings Date BLTE Earnings Date GLPG Earnings Date ARQT Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? This page (NASDAQ:MLYS) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTop Picks for Trump’s Pro-Crypto AmericaThe Crypto ETF Windfall: 27 Experts Tell All (Free) Don't miss your chance to see exactly what crypto's eli...Crypto 101 Media | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mineralys Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MLYS Stock Alerts